Two analyses show Fycompa (Eisai) effective for Epilepsy
Two new analyses on clinical experience with Fycompa (perampanel), from Eisai, show it is effective and well tolerated in patients with difficult-to-treat partial Epilepsy. The results describe the first real life experiences of perampanel as an adjunctive therapy. In the first study, on 45 patients followed up for at least six months, 47% had a reduction in seizure frequency of at least 50% compared to baseline, and 16% became seizure free. 62% (n=28) of patients experienced adverse events.
In a second study of patients who had intractable epilepsy (52.6% with temporal lobe epilepsy) for an average of 23.7 years, and had previously been treated with an average number of nine AEDs, 21.1% experienced more than a 50% decrease of seizure frequency with perampanel, and a further five patients (26.3%) observed a positive effect, although less than a 50% reduction in seizure frequency. Four patients discontinued treatment. Data was presented at a meeting of the German and Austrian Societies for Epileptology and the Swiss League Against Epilepsy.
Related news and insights
AbbVie has announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the approval of risankizumab (Skyrizi 150 mg, subcutaneous injection at week 0, week 4 and every 12 weeks thereafter) alone or in combination with methotrexate (MTX), for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (DMARDs).
Merck Inc., announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Vaxneuvance (Pneumococcal 15-valent Conjugate Vaccine) for active immunization for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae in individuals 18 years of age and older. The CHMP recommendation will now be reviewed by the European Commission for marketing authorization in the European Union, and a final decision is expected by the end of the year.
Merck Inc., and Eisai announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted positive opinions recommending approval of the combination of Keytruda, Merck’s anti-PD-1 therapy, plus Lenvima (marketed as Kisplyx in the European Union [EU]) for the treatment of advanced renal cell carcinoma [RCC]), the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, for two different indications.